Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28523662 | 1.00 | FKBP1A (0.35) | FKBP1APTGER2PTGER3PTGDRDUT | |
| SCHEMBL959880 | 0.88 | FKBP1A (0.34) | FKBP1APTGER2PTGER3PTGDRDUT | |
| SCHEMBL24795958 | 0.87 | TP53 (0.38) | FKBP1APTGER2PTGER3PTGDRDUT | |
| SCHEMBL1401064 | 0.87 | TP53 (0.38) | FKBP1APTGER2PTGER3PTGDRDUT | |
| SCHEMBL27650285 | 0.87 | PTGER4 (0.39) | FKBP1APTGER2PTGER3PTGER4 | |
| SCHEMBL8708692 | 0.86 | FKBP1A (0.35) | FKBP1ADUTTOP2A | |
| SCHEMBL963144 | 0.85 | FKBP1A (0.32) | FKBP1ADUT | |
| SCHEMBL1401084 | 0.83 | PDK2 (0.41) | FKBP1APTGER2PTGER3DUTPTGER4 | |
| SCHEMBL24795959 | 0.83 | PDK2 (0.41) | FKBP1APTGER2PTGER3DUTPTGER4 | |
| SCHEMBL1576228 | 0.82 | DUT (0.34) | FKBP1ADUTTOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-8501793-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-7833995-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1707208-A1 | BLOOD FLOW PROMOTERS FOR CAUDA EQUINA TISSUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | PTGFR, PTGIS, PTGIR | FKBP1A 1008/4885PTGER2 100/4885PTGER3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.